Lumigan users reporting longer, thicker lashes
- Ophthalmologists have long warned that Lumigan, AbbVie’s bimatoprost eye drop for glaucoma and ocular hypertension, can make treated patients’ eyelashes grow longer, thicker and darker. - The effect appears in official prescribing information: Lumigan’s label warns of increased eyelash length, thickness and number, and Latisse uses the same drug to grow lashes. - The lash change is a recognized prostaglandin-drug effect, not a new safety alert, and can leave eyes looking uneven if only one eye is treated. (rxabbvie.com)
Glaucoma is damage from pressure inside the eye, and one common treatment lowers that pressure by helping fluid drain out more easily. Bimatoprost, sold as Lumigan, is one of those drops. (medlineplus.gov) (rxabbvie.com) Doctors have also long seen a cosmetic effect from the same medicine: eyelashes in the treated eye can grow longer, thicker and darker. Ophthalmology Times described that link in a July 30, 2008 report on Lumigan users. (ophthalmologytimes.com) Andrew Iwach, a San Francisco glaucoma specialist and American Academy of Ophthalmology spokesperson quoted in that report, said there was “no question” the drug can make eyelashes grow in many patients. The article identified bimatoprost ophthalmic solution 0.03% as the drop most commonly associated with the effect. (ophthalmologytimes.com) This is not a separate beauty product accidentally discovered by patients after the fact. The United States Food and Drug Administration-approved label for Lumigan warns patients about gradual eyelash changes, including increased length, thickness and number of lashes. (accessdata.fda.gov) (rxabbvie.com) The same chemical also became a cosmetic drug. Latisse, which contains bimatoprost 0.03%, is approved to treat inadequate eyelashes by increasing their growth, including length, thickness and darkness. (accessdata.fda.gov) That overlap helps explain why eye doctors bring up lashes when counseling glaucoma patients. A pressure-lowering drop and an eyelash-growth treatment can share the same active ingredient while being used in different ways. (mayoclinic.org) (accessdata.fda.gov) The labeling also warns that the change may not look symmetrical. If only one eye is treated, patients can end up with differences between eyes in lash length, thickness, pigmentation, number or even direction of growth. (rxabbvie.com) (dailymed.nlm.nih.gov) Some of the pigment changes tied to prostaglandin drugs can last, especially iris darkening, while the lash changes are described as usually reversible after treatment stops. The product information separately warns about eyelid skin darkening and hair growth outside the treated area. (rxabbvie.com) (accessdata.fda.gov) So the lash effect attached to Lumigan is real, documented and familiar to eye specialists. It is best understood as a known side effect of a glaucoma medicine that later became the basis for an eyelash-growth brand. (ophthalmologytimes.com) (accessdata.fda.gov)
